NZ716156A - Novel indolizine derivatives useful as bcl-2 inhibitors, method for the production thereof and pharmaceutical compositions containing same - Google Patents

Novel indolizine derivatives useful as bcl-2 inhibitors, method for the production thereof and pharmaceutical compositions containing same

Info

Publication number
NZ716156A
NZ716156A NZ716156A NZ71615614A NZ716156A NZ 716156 A NZ716156 A NZ 716156A NZ 716156 A NZ716156 A NZ 716156A NZ 71615614 A NZ71615614 A NZ 71615614A NZ 716156 A NZ716156 A NZ 716156A
Authority
NZ
New Zealand
Prior art keywords
bcl
inhibitors
production
pharmaceutical compositions
compositions containing
Prior art date
Application number
NZ716156A
Other languages
English (en)
Inventor
Jérôme-Benoît Starck
Jean-Michel Henlin
James Edward Paul Davidson
James Brooke Murray
Tiran Arnaud Le
Nanteuil Guillaume De
Diguarher Thierry Le
Olivier Geneste
I-Jen Chen
Original Assignee
Servier Lab
Vernalis R&D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50023640&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ716156(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier Lab, Vernalis R&D Ltd filed Critical Servier Lab
Publication of NZ716156A publication Critical patent/NZ716156A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ716156A 2013-07-23 2014-07-22 Novel indolizine derivatives useful as bcl-2 inhibitors, method for the production thereof and pharmaceutical compositions containing same NZ716156A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1357265A FR3008976A1 (fr) 2013-07-23 2013-07-23 "nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent"
PCT/FR2014/051885 WO2015011397A1 (fr) 2013-07-23 2014-07-22 Nouveaux dérivés d'indolizine, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent

Publications (1)

Publication Number Publication Date
NZ716156A true NZ716156A (en) 2019-05-31

Family

ID=50023640

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ716156A NZ716156A (en) 2013-07-23 2014-07-22 Novel indolizine derivatives useful as bcl-2 inhibitors, method for the production thereof and pharmaceutical compositions containing same

Country Status (50)

Country Link
US (3) US9944620B2 (https=)
EP (1) EP3024833B1 (https=)
JP (1) JP6458029B2 (https=)
KR (1) KR102007516B1 (https=)
CN (1) CN105579450B (https=)
AP (1) AP2016008990A0 (https=)
AR (1) AR099913A1 (https=)
AU (1) AU2014294867B2 (https=)
BR (1) BR112016001328B1 (https=)
CA (1) CA2918217C (https=)
CL (1) CL2016000063A1 (https=)
CR (1) CR20160031A (https=)
CU (1) CU24380B1 (https=)
CY (1) CY1119652T1 (https=)
DK (1) DK3024833T3 (https=)
DO (1) DOP2016000014A (https=)
EA (1) EA030323B1 (https=)
ES (1) ES2650814T3 (https=)
FR (1) FR3008976A1 (https=)
GE (1) GEP20176804B (https=)
GT (1) GT201600017A (https=)
HK (1) HK1222394A1 (https=)
HR (1) HRP20171752T1 (https=)
HU (1) HUE037498T4 (https=)
IL (1) IL243742B (https=)
JO (1) JO3310B1 (https=)
LT (1) LT3024833T (https=)
MA (1) MA38803A1 (https=)
MD (1) MD4643C1 (https=)
ME (1) ME02922B (https=)
MX (1) MX365916B (https=)
MY (1) MY178251A (https=)
NI (1) NI201600015A (https=)
NO (1) NO3024833T3 (https=)
NZ (1) NZ716156A (https=)
PE (1) PE20160240A1 (https=)
PH (1) PH12016500057A1 (https=)
PL (1) PL3024833T3 (https=)
PT (1) PT3024833T (https=)
RS (1) RS56451B1 (https=)
RU (1) RU2693629C2 (https=)
SA (1) SA516370448B1 (https=)
SG (2) SG10201800580XA (https=)
SI (1) SI3024833T1 (https=)
TN (1) TN2016000014A1 (https=)
TW (1) TWI511969B (https=)
UA (1) UA119243C2 (https=)
UY (1) UY35626A (https=)
WO (1) WO2015011397A1 (https=)
ZA (1) ZA201600350B (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2986002B1 (fr) 2012-01-24 2014-02-21 Servier Lab Nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3008976A1 (fr) * 2013-07-23 2015-01-30 Servier Lab "nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent"
AU2017300738A1 (en) 2016-07-22 2019-02-07 Les Laboratoires Servier Combination of a BCL-2 inhibitor and a MCL-1 inhibitor, uses and pharmaceutical compositions thereof
WO2018158225A1 (en) 2017-02-28 2018-09-07 Les Laboratoires Servier Combination of a bcl-2 inhibitor and a mdm2 inhibitor, uses and pharmaceutical compositions thereof
RU2764243C2 (ru) 2017-09-22 2022-01-14 ДЖУБИЛАНТ ЭПИПЭД ЭлЭлСи Гетероциклические соединения в качестве ингибиторов PAD
AU2018352142B2 (en) 2017-10-18 2022-08-25 Jubilant Epipad LLC Imidazo-pyridine compounds as PAD inhibitors
FR3072679B1 (fr) 2017-10-25 2020-10-30 Servier Lab Nouveaux derives macrocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US11629135B2 (en) 2017-11-06 2023-04-18 Jubilant Prodell Llc Pyrimidine derivatives as inhibitors of PD1/PD-L1 activation
PT3704120T (pt) 2017-11-24 2024-07-03 Jubilant Episcribe Llc Compostos heterocíclicos como inibidores de prmt5
MX2020009517A (es) 2018-03-13 2021-01-20 Jubilant Prodel LLC Compuestos biciclicos como inhibidores de la interaccion/activacio n de pdl/pd-l1.
WO2020231723A1 (en) * 2019-05-13 2020-11-19 Ecolab Usa Inc. 1,2,4-triazolo[1,5-a] pyrimidine derivative as copper corrosion inhibitor
JP7773734B2 (ja) * 2021-03-12 2025-11-20 エイル セラピューティクス，インコーポレイテッド Ｂｃｌ－２阻害剤としてのテトラヒドロインドリジン－１－カルボキサミドを有する化合物
CA3240077A1 (en) * 2021-12-29 2023-07-06 Volodymyr KYSIL Bcl-2 inhibitors
US20250387504A1 (en) 2022-05-20 2025-12-25 Novartis Ag Antibody-drug conjugates of antineoplastic compounds and methods of use thereof
PY24103486A (es) 2023-11-22 2025-06-06 Servier Lab Conjugados de anticuerpo anti-cd74-fármaco y métodos de uso de los mismos
AR134424A1 (es) 2023-11-22 2026-01-14 Novartis Ag Conjugados de anticuerpo anti-cd7-fármaco y métodos de uso de los mismos

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0212760A (pt) * 2001-09-19 2004-12-07 Aventis Pharma Sa Compostos quìmicos
EP1501514B1 (en) 2002-05-03 2012-12-19 Exelixis, Inc. Protein kinase modulators and methods of use
US20050070570A1 (en) 2003-06-18 2005-03-31 4Sc Ag Novel potassium channels modulators
AU2005277223C1 (en) * 2004-08-20 2009-05-21 The Regents Of The University Of Michigan Small molecule inhibitors of anti-apoptotic Bcl-2 family members and the uses thereof
EP1778206A4 (en) * 2004-08-20 2009-08-05 Univ Michigan SMALL MOLECULE INHIBITORS FROM MEMBERS OF THE ANTIOPTOTIC BCL-2 FAMILY AND USES THEREOF
AU2006331765A1 (en) 2005-12-22 2007-07-05 Wyeth Substituted isoquinoline-1,3(2H,4H)-diones, 1-thioxo-1,4-dihydro-2H-isoquinoline-3-ones and 1,4-dihydro-3(2H)-isoquinolones and use thereof as kinase inhibitor
US7902218B2 (en) 2006-12-12 2011-03-08 Bristol-Myers Squibb Company Substituted tetrahydroisoquinolines as β-secretase inhibitors
MY162157A (en) 2007-04-16 2017-05-31 Abbott Lab Substituted indole mcl-1 inhibitors
MX2009012610A (es) 2007-05-22 2009-12-11 Astellas Pharma Inc Compuesto de tetrahidroisoquinolina 1-sustituido.
EP2225207A2 (en) 2007-11-30 2010-09-08 Biota Scientific Management Pty. Ltd. Tetrahydro-isoquinoline ppat inhibitors as antibacterial agents
WO2009102468A1 (en) 2008-02-13 2009-08-20 Cgi Pharmaceuticals, Inc. 6-aryl-imidaz0[l, 2-a] pyrazine derivatives, method of making, and method of use thereof
ES2478820T3 (es) 2008-02-15 2014-07-23 Tufts University Tratamiento de degeneración macular
JP2014521595A (ja) * 2011-05-25 2014-08-28 ブリストル−マイヤーズ スクイブ カンパニー 抗アポトーシスＢｃｌ阻害剤として有用な置換スルホンアミド
BR112014015308A8 (pt) 2011-12-23 2017-06-13 Novartis Ag compostos para inibição da interação de bcl2 com contrapartes de ligação
WO2013096051A1 (en) 2011-12-23 2013-06-27 Novartis Ag Compounds for inhibiting the interaction of bcl2 with binding partners
US9126980B2 (en) 2011-12-23 2015-09-08 Novartis Ag Compounds for inhibiting the interaction of BCL2 with binding partners
EP2794591A1 (en) 2011-12-23 2014-10-29 Novartis AG Compounds for inhibiting the interaction of bcl2 with binding partners
EP2794592A1 (en) 2011-12-23 2014-10-29 Novartis AG Compounds for inhibiting the interaction of bcl2 with binding partners
EP2609926B1 (en) 2011-12-30 2013-10-23 Jakob Hraschan Prevention or treatment of painful polyneuropathies by administration of an aluminosilicate
FR2986002B1 (fr) * 2012-01-24 2014-02-21 Servier Lab Nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3008976A1 (fr) * 2013-07-23 2015-01-30 Servier Lab "nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent"
FR3008979B1 (fr) 2013-07-23 2015-07-24 Servier Lab Nouveaux derives phosphates, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
JP2016525536A (ja) 2016-08-25
PH12016500057B1 (en) 2016-03-28
IL243742B (en) 2019-06-30
JP6458029B2 (ja) 2019-01-23
PH12016500057A1 (en) 2016-03-28
ES2650814T3 (es) 2018-01-22
CY1119652T1 (el) 2018-04-04
BR112016001328A2 (https=) 2017-07-25
HK1223360A1 (zh) 2017-07-28
DOP2016000014A (es) 2016-03-15
RU2016105999A (ru) 2017-08-28
CN105579450B (zh) 2017-12-12
SG10201800580XA (en) 2018-03-28
DK3024833T3 (en) 2017-12-18
US20190359595A1 (en) 2019-11-28
ZA201600350B (en) 2017-05-31
RU2016105999A3 (https=) 2018-04-28
HK1222394A1 (zh) 2017-06-30
MY178251A (en) 2020-10-07
TN2016000014A1 (fr) 2017-07-05
KR102007516B1 (ko) 2019-08-05
CU20160011A7 (es) 2016-05-30
CN105579450A (zh) 2016-05-11
NI201600015A (es) 2016-02-11
US20180186771A1 (en) 2018-07-05
LT3024833T (lt) 2017-10-25
CA2918217C (fr) 2018-06-12
PE20160240A1 (es) 2016-04-30
MX2016000906A (es) 2016-05-05
EP3024833A1 (fr) 2016-06-01
JO3310B1 (ar) 2018-09-16
IL243742A0 (en) 2016-04-21
EA030323B1 (ru) 2018-07-31
TW201504238A (zh) 2015-02-01
AR099913A1 (es) 2016-08-31
NO3024833T3 (https=) 2018-02-03
UY35626A (es) 2015-02-27
CR20160031A (es) 2016-04-04
MD4643B1 (ro) 2019-08-31
AU2014294867B2 (en) 2018-10-04
RU2693629C2 (ru) 2019-07-03
GT201600017A (es) 2018-10-08
SA516370448B1 (ar) 2018-12-12
MA38803A1 (fr) 2017-10-31
FR3008976A1 (fr) 2015-01-30
HUE037498T2 (hu) 2018-08-28
TWI511969B (zh) 2015-12-11
AU2014294867A1 (en) 2016-02-11
US9944620B2 (en) 2018-04-17
MX365916B (es) 2019-06-20
GEP20176804B (en) 2018-01-10
SI3024833T1 (sl) 2017-12-29
HUE037498T4 (hu) 2018-11-28
US20160176848A1 (en) 2016-06-23
CU24380B1 (es) 2019-02-04
CL2016000063A1 (es) 2016-08-19
UA119243C2 (uk) 2019-05-27
RS56451B1 (sr) 2018-01-31
MD20160016A2 (ro) 2016-07-31
US10414754B2 (en) 2019-09-17
KR20160034387A (ko) 2016-03-29
WO2015011397A1 (fr) 2015-01-29
MD4643C1 (ro) 2020-03-31
CA2918217A1 (fr) 2015-01-29
HRP20171752T1 (hr) 2017-12-29
SG11201600318RA (en) 2016-02-26
PL3024833T3 (pl) 2018-02-28
ME02922B (me) 2018-04-20
BR112016001328B1 (pt) 2022-03-03
EP3024833B1 (fr) 2017-09-06
EA201600124A1 (ru) 2016-07-29
PT3024833T (pt) 2017-10-06
AP2016008990A0 (en) 2016-01-31

Similar Documents

Publication Publication Date Title
NZ716156A (en) Novel indolizine derivatives useful as bcl-2 inhibitors, method for the production thereof and pharmaceutical compositions containing same
JO3160B1 (ar) مشتقات الفوسفات الجديدة, طريقة تحضيرها والتركيبات الدوائية التي تحتوي عليها
MY172811A (en) New indolizine compounds, a process for their preparation and pharmaceutical compositions containing them
JO3275B1 (ar) مشتقات بيرول جديدة وطريقة لتحضيرها وتركيبات صيدلانية التي تحتوي عليها
PH12017502246B1 (en) New hydroxyester derivatives, a process for their preparation and pharmaceutical compositions containing them
MD4516B1 (ro) Derivaţi noi de tienopirimidină, procedeu de preparare a acestora, compoziţii farmaceutice care îi conţin şi utilizările lor în calitate de agenţi proapoptotici
MX359418B (es) Pteridinas como inhibidores del receptor del factor de crecimiento de fribroblasto (fgfr).
PH12015501648A1 (en) 2-aminopyrimidine derivatives for the treatment of viral infections
PH12016502291A1 (en) Indolizine derivatives as phosphoinositide 3-kinases inhibitors
MX363347B (es) Sal de omecamtiv mecarbilo y proceso para preparar la sal.
NZ716155A (en) New isoindoline or isoquinoline compounds, a process for their preparation and pharmaceutical compositions containing them
PH12014501991B1 (en) Phenicol antibacterials
UA117020C2 (uk) Нові сполуки індолу і піролу, спосіб їх одержання і фармацевтичні композиції, що їх містять
TW201613864A (en) Novel compounds
MX2016008247A (es) Derivados de acido heteroaril butanoico como inhibidores de lta4h.
MX363631B (es) Composiciones y metodos para tratar infecciones bacterianas.
IN2015DN02109A (https=)
PH12017500323A1 (en) P38 map kinase inhibiting indanyl urea compounds
MX360040B (es) Nuevo agente antibacteriano derivado de florfenicol unido a sulfoximina y el uso del mismo en el tratamiento de infecciones bacterianas en ganado vacuno.
MX2014004742A (es) Nuevos agentes antibacterianos de fenicol.
MX369303B (es) Nuevos complejos de agomelatina y de acidos sulfonicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 JUL 2021 BY AJ PARK

Effective date: 20200529

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 JUL 2022 BY AJ PARK

Effective date: 20210604

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 JUL 2023 BY AJ PARK

Effective date: 20220518

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 JUL 2024 BY AJ PARK

Effective date: 20230505

LAPS Patent lapsed